Dyne's exon 51 Duchenne drug faces FDA verdict within weeks, with $1.13bn in cash

Dyne Therapeutics will learn within about 11 weeks whether it can bring its first product to the US market. The company said on 5 November that the FDA has accepted its biologics licence application for z-rostudirsen, a treatment for Duchenne muscular dystrophy in patients whose mutations can be addressed by skipping exon 51, and set a goal date of 21 January 2027.

The application was accepted with a priority designation. As context, that status is meant to shorten the target review time for medicines that could meaningfully improve care for serious conditions. The goal date is the point by which the agency aims to finish its assessment. The outcome will decide whether another exon 51 option joins the US market, a point of interest for market-access teams working in exon-skipping.

The financial picture shows a company spending ahead of a possible launch. Dyne reported a third-quarter net loss of $193.6m, which it characterised as larger than before. It held $1.134bn in cash and expects that to fund operations into the second quarter of 2028, a window that spans both the regulatory decision and the next major data release.

That release comes from the company's second programme. Alongside the financial results, Dyne presented one-year data from the Phase 1/2 ACHIEVE study of z-basivarsen in myotonic dystrophy type 1, and said topline results from the registrational cohort should arrive in the first quarter of 2027.